Tesamorelin vs Sermorelin: Same Target, Very Different Evidence

The short answer

• Both are GHRH analogues, binding the growth hormone releasing hormone receptor on pituitary somatotrophs. Neither touches the ghrelin receptor.
• Tesamorelin is Approved in the US for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, on two phase 3 trials in over 800 people. It holds Human trials status for liver fat in HIV-associated fatty liver disease and for visceral fat in non-HIV obesity with reduced GH secretion.
• Sermorelin holds Human trials status, historically approved, for paediatric idiopathic GH deficiency and pituitary diagnostic testing. For the adult body-composition uses it is actually sold for, it is Preclinical only.
• Neither has a trial supporting fat loss, muscle gain or performance in healthy adults. Tesamorelin’s label states it is not indicated for weight loss management because it is weight-neutral.
• As of September 2026 there is no authorised sermorelin product in the US or Canada, and none in Canada. Both are prohibited at all times under WADA S2.2.4.

Same receptor, different molecule

Any honest tesamorelin vs sermorelin comparison starts with what they share. Sermorelin is the first 29 amino acids of human GHRH, amidated at the C-terminus; the 1-29 fragment keeps essentially full receptor activity, which is why it was developed. Tesamorelin is the full 44-amino-acid human GHRH, also amidated, with a trans-3-hexenoyl group on the tyrosine at position 1 that blocks dipeptidyl peptidase IV cleavage.

Both act one step above the pituitary, so GH release stays pulsatile and subject to somatostatin tone and IGF-1 negative feedback. Both are useless if the somatotrophs are gone, which is exactly why sermorelin was once approved as a diagnostic agent for distinguishing hypothalamic from pituitary GH deficiency. For the wider GH-axis picture, see CJC-1295 vs sermorelin vs ipamorelin.

Both are minutes-scale drugs

Sermorelin’s disappearance half-time is about 4.3 minutes during constant IV infusion in normal men (Soule 1994). Adding a D-Ala2 substitution, the modification behind “mod GRF 1-29”, stretches that to about 6.7 minutes. Tesamorelin lands in the same order of magnitude: its current FDA labels give a mean half-life of 8 minutes for Egrifta SV and 11 minutes for Egrifta WR, with subcutaneous bioavailability under 4%. The hexenoyl modification extends the half-life from minutes to minutes, worth saying plainly, because it is often described as if it produced a long-acting drug.

And yet 26 weeks of daily tesamorelin produced an 81% sustained rise in IGF-1. The effect comes from one brief GH pulse per day and the integrated IGF-1 exposure that follows, not from continuous drug presence. Anyone reasoning “short half-life means weak drug” has it backwards, and anyone reasoning “longer-acting is better” should note that the long-acting GHRH concept was abandoned after a death in a phase 2 trial in the same population where the short-acting design completed phase 3. Any product claiming 24-hour elevated growth hormone from plain sermorelin is misrepresenting its own pharmacology.

The evidence gap, side by side

What tesamorelin has. Two identically designed phase 3 trials plus extensions, totalling over 800 HIV-positive adults with visceral fat accumulation. In the pivotal trial of 412 patients on 2 mg daily for 26 weeks, visceral adipose tissue fell 15.2% against a 5.0% rise on placebo, and IGF-1 rose 81.0% against a 5.0% fall, with no significant difference in glycaemic measures (Falutz 2007). Later phase 2 work extended this: in HIV-associated fatty liver disease, 61 patients on 2 mg daily for 12 months showed an absolute hepatic fat fraction effect of -4.1%, with 35% against 4% of placebo reaching a fraction below 5% (Stanley 2019). And in non-HIV obese subjects with reduced GH secretion, visceral adipose tissue fell by a treatment effect of -35 cm2 with no significant change in abdominal subcutaneous fat (Makimura 2012), which is real evidence of visceral selectivity rather than an inference.

What sermorelin has. Genuine regulatory-grade data, for two things that are not what it is sold for: diagnosing whether a pituitary can release GH, and increasing height velocity in children with idiopathic GH deficiency. The adult literature is a small set of 1990s studies in healthy older men and women, mostly 1 to 6 months, measuring GH and IGF-1 rather than clinical outcomes, one of them using an analogue rather than sermorelin itself.

No trial has tested the flat adult dose that compounding pharmacies sell against placebo for any outcome. The closest proxy is a systematic review of growth hormone itself in the healthy elderly: small body-composition changes, increased adverse events, no functional benefit (Liu 2007).

Doses that were actually studied

Tesamorelin’s entire efficacy literature used 2 mg subcutaneously daily of the original formulation, over 26 weeks to 12 months. The current US label doses are formulation-adjusted equivalents, Egrifta SV at 1.4 mg once daily and Egrifta WR at 1.28 mg once daily, both for the approved HIV lipodystrophy indication. The two are explicitly not substitutable, and confusing them is a real dosing error the label warns about.

Sermorelin’s approved regimens were weight-based: 0.03 mg/kg once daily at bedtime subcutaneously for paediatric idiopathic GH deficiency, and a single 1 mcg/kg intravenous dose for the diagnostic product. Every adult research protocol was weight-based or infusion-based.

None of that validates a flat adult microgram dose, which is how sermorelin is sold. The bedtime timing in circulation is the most defensible part of the convention, since it extrapolates from the approved paediatric regimen. The dose itself has no trial behind it, and blended vials pairing a GHRH analogue with a ghrelin-receptor agonist have no human data as a combination. This site does not publish those regimens.

The legal positions are not the same either

Tesamorelin in the US. Approved, under BLA 022505. Egrifta was approved in November 2010 as an NDA, and the application was deemed to be a BLA on 23 March 2020, because tesamorelin’s 44 residues sit above the 40-amino-acid drug versus biologic boundary. The consequence is decisive: the 503A and 503B compounding exemptions apply to drugs approved under section 505, not to biologics licensed under section 351 of the Public Health Service Act. Compounded tesamorelin has no lawful pathway at all in the US.

Sermorelin in the US. Not marketed. Geref and Geref Diagnostic were discontinued in 2008, the FDA withdrew approval effective 18 June 2009, and the agency formally determined in 2013 that the withdrawal was not for reasons of safety or effectiveness, which matters because a safety-based withdrawal would bar compounding outright. Sermorelin appears in none of the three 503A categories and has no USP or NF monograph. Pharmacies widely treat it as eligible on the theory that it is a component of a once-approved drug, a reading the agency has not confirmed in writing, so “sermorelin is legal to compound” is an industry position rather than a documented determination.

Canada, both. No authorised sermorelin product exists, and both Egrifta DINs are cancelled. Both peptides were named among unauthorized injectables seized in Health Canada’s 1 August 2025 advisory, and its 9 April 2026 advisory states that a research-use label confers no legal status.

Safety: the label numbers are the useful part

Tesamorelin has the best-documented safety dataset in this category, because it has a current label. Most common reactions above 5%: arthralgia, injection-site erythema and pruritus, pain in extremity, peripheral oedema, myalgia. Contraindications are disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity, and pregnancy. Among patients on 26 weeks of therapy, 47% had IGF-1 above 2 standard deviation scores and 36% above 3, and the label advises considering discontinuation for persistent elevations above roughly 3 SDS where the efficacy response is not robust. The glucose signal is concrete: 5% against 1% of placebo reached HbA1c of 6.5% or higher by week 26, hazard odds ratio 3.3 (95% CI 1.4 to 9.6). Three label limitations of use each contradict a common marketing claim: long-term cardiovascular safety is not established, the drug is not indicated for weight loss management, and no data support improved antiretroviral compliance.

Sermorelin’s own reported events are mostly injection-site reactions, flushing, headache and nausea. The class risks of raising GH and IGF-1 belong to GH physiology rather than to a particular molecule, so assume they apply. The unresolved question for both is IGF-1 and cancer: higher circulating IGF-1 is associated with increased risk of some cancers in observational meta-analysis (Renehan 2004), which is association rather than causation, and no GHRH analogue trial has been large enough to test it.

The bottom line

Tesamorelin is a narrow, legitimate, approved drug with phase 3 data in one population, a current label, a real glucose signal and frequent IGF-1 elevation. Sermorelin is real pharmacology with a real regulatory history, sold today for an indication that history never covered, at a dose no trial ever used. Sharing a receptor does not transfer evidence between them. See the tesamorelin and sermorelin profiles for the full records.

Education only. This page is educational. Most compounds referenced are not approved for human use, and a “research use only” label carries no legal status of its own. Nothing here constitutes medical advice, diagnosis, or treatment.

Sources

• Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007.
• Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism, 2010.
• Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 2019.
• Makimura H, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism, 2012.
• Soule S, King JA, Millar RP. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. Journal of Clinical Endocrinology and Metabolism, 1994.
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 1999.
• Liu H, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine, 2007.
• Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 2004.